Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma
Status:
Completed
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, tolerability and recommended phase 2
dose of a new drug, known as IMP321, in combination with pembrolizumab when given to patients
with unresectable or metastatic melanoma.
Phase:
Phase 1
Details
Lead Sponsor:
Immutep Australia Pty. Ltd. Prima BioMed Australia Pty. Ltd.